Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-01-20 @ 12:46 AM
Study NCT ID:
NCT05438420
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2022-05-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Sponsor:
Qurient Co., Ltd.
Organization: